What is Palisade Bio, Inc.'s earnings per share (EPS)?

Palisade Bio, Inc. (PALI) reported diluted earnings per share of -$0.30 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Palisade Bio, Inc. (PALI) Financials

PALI

FY2025 annual

Revenue $0 YoY not available

Net Income -$16.8M -16.2% YoY

EPS (Diluted) -$0.30 YoY not available

Operating Cash Flow -$10.8M +11.0% YoY

Market Cap $250.9M as of Oct 3, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.1x on $121.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PALI SEC filings page.

Palisade Bio, Inc. (PALI) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PALI FY2025 2026-10-04

Palisade remains a development-stage business: financing, not operations, supplied the 2025 balance-sheet expansion while losses continued.

FY2025 operating cash flow of -$10.8M was less negative than the net loss of $16.8M, showing that accounting losses and cash use did not move one-for-one. Meanwhile, financing supplied $134.4M, so the sharp asset and equity expansion was funded externally while operations remained cash-consuming.

R&D spending fell from $16.0M in FY2024 to $10.2M in FY2025. Yet operating loss widened to $18.1M from $14.9M, so lower development spending did not translate into near-term earnings improvement.

Liabilities of $5.0M against equity of $129.4M indicate an equity-financed balance sheet rather than one dependent on debt. Current assets of $134.2M versus current liabilities of $4.6M further show that the reported balance-sheet resources are concentrated in short-term assets.

Financial Health Signals

Financial health score not available

Palisade Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/7

Palisade Bio, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Palisade Bio, Inc. reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Palisade Bio, Inc. reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$500K

Palisade Bio, Inc. generated $500K in revenue in Q2 2026.

EBITDA

-$11.7M

YoY-311.6%

QoQ-8.8%

Palisade Bio, Inc.'s EBITDA was -$11.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 311.6% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.

Net Income

-$10.6M

YoY-279.8%

QoQ-10.1%

Palisade Bio, Inc. reported -$10.6M in net income in Q2 2026. This represents a decrease of 279.8% from the same quarter a year earlier. Against the prior quarter it is down 10.1%.

EPS (Diluted)

-$0.05

QoQ0.0%

Palisade Bio, Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.

Cash & Balance Sheet

Cash & Debt

$125.2M

YoY+2210.7%

QoQ-5.6%

5Y CAGR+58.1%

10Y CAGR+27.4%

Palisade Bio, Inc. held $125.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

174M

QoQ+0.4%

5Y CAGR+68.3%

10Y CAGR+4.3%

Palisade Bio, Inc. had 174M shares outstanding in Q2 2026. Against the prior quarter it is up 0.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-8.7%

YoY+97.6pp

QoQ-1.2pp

Palisade Bio, Inc.'s ROE was -8.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 97.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$6.0M

YoY+258.2%

QoQ0.0%

Palisade Bio, Inc. invested $6.0M in research and development in Q2 2026. This represents an increase of 258.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

PALI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$0	$0-100.0%	$250K	$0	N/A	$14K-12.2%	$15K-94.1%	$260K0.0%	$260K+1500.4%	$16K+56.0%	$10K-44.7%	$19K-82.9%	$110K-73.0%	$408K+4.4%	$391K
R&D Expenses	N/A	$10.2M-36.3%	$16.0M+132.1%	$6.9M+5.3%	$6.5M+169.4%	$2.4M+20.4%	$2.0M-50.3%	$4.1M+2.6%	$4.0M-51.1%	$8.1M-38.5%	$13.2M+4.1%	$12.6M+51.1%	$8.4M+14.8%	$7.3M+19.3%	$6.1M-17.0%	$7.4M
SG&A Expenses	N/A	$7.9M+35.7%	$5.8M-6.5%	$6.2M-29.2%	$8.8M-5.8%	$9.3M+50.2%	$6.2M+35.2%	$4.6M+0.6%	$4.6M-16.7%	$5.5M-27.0%	$7.5M+14.8%	$6.5M-28.2%	$9.1M+70.0%	$5.3M+1989.1%	$256K0.0%	$256K
Operating Income	N/A	-$18.1M-21.5%	-$14.9M-13.7%	-$13.1M+16.9%	-$15.7M+62.4%	-$41.9M-350.2%	-$9.3M-7.7%	-$8.6M-4.5%	-$8.3M+37.9%	-$13.3M+35.5%	-$20.6M-7.7%	-$19.2M-9.9%	-$17.4M-39.2%	-$12.5M-23.3%	-$10.2M+21.8%	-$13.0M
EBITDA	N/A	-$18.1M-21.5%	-$14.9M-13.7%	-$13.1M+16.9%	-$15.7M+62.4%	-$41.9M-350.3%	-$9.3M-9.5%	-$8.5M-5.1%	-$8.1M+38.0%	-$13.0M+35.9%	-$20.3M-7.9%	-$18.8M-10.1%	-$17.1M-39.2%	-$12.3M-23.5%	-$9.9M+22.3%	-$12.8M
Interest Expense	N/A	$10K-16.7%	$12K-20.0%	$15K+15.4%	$13K-99.5%	$2.4M+920.4%	$235K+2534.5%	$9K+15.9%	$8K-95.2%	$159K-86.1%	$1.1M-37.2%	$1.8M+12.1%	$1.6M+16.2%	$1.4M+51558.9%	$3K+228.7%	$821
Income Tax	N/A	$0	$0	$0	$0	$0-100.0%	$1K	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$16.8M-16.2%	-$14.4M-17.4%	-$12.3M+13.7%	-$14.3M+46.4%	-$26.6M-157.9%	-$10.3M-23.6%	-$8.4M-69.6%	-$4.9M+68.6%	-$15.7M+25.7%	-$21.1M-0.8%	-$20.9M+7.6%	-$22.6M-14.1%	-$19.8M-95.9%	-$10.1M+19.1%	-$12.5M
EPS (Basic)	N/A	-$0.30+97.1%	-$10.19+62.3%	-$27.01-63.4%	-$16.53+88.4%	-$142.95-3742.7%	-$3.72	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.60	-$0.30	-$10.19	-$27.01	-$16.53	-$169.74	-$3.72	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	56M	1M	456,014	880,311	186,958	3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$500K	$0	N/A	$0	$0	$0	N/A	$0-100.0%
R&D Expenses	$6.0M+258.2%	$6.0M+531.6%	N/A	$1.4M-91.3%	$1.7M-36.3%	$950K-57.1%	N/A	$16.0M+660.5%
SG&A Expenses	$4.8M+310.8%	$4.4M+219.9%	N/A	$1.5M+4.9%	$1.2M-26.2%	$1.4M-6.8%	N/A	$1.5M-13.0%
Operating Income	-$11.7M-311.5%	-$10.7M-365.3%	N/A	-$2.9M+18.7%	-$2.8M+32.5%	-$2.3M+37.1%	N/A	-$3.6M+4.9%
EBITDA	-$11.7M-311.6%	-$10.7M-365.5%	N/A	-$2.9M+18.7%	-$2.8M+32.5%	-$2.3M+37.1%	N/A	-$3.6M+4.9%
Interest Expense	$0-100.0%	$1K0.0%	N/A	$5K-16.7%	$2K0.0%	$1K0.0%	N/A	$6K-25.0%
Net Income	-$10.6M-279.8%	-$9.6M-330.5%	N/A	-$2.9M+17.8%	-$2.8M+31.8%	-$2.2M+36.8%	N/A	-$3.5M+3.0%
EPS (Basic)	-$0.05+91.4%	-$0.05+89.4%	$1.08+256.5%	-$0.38+83.6%	-$0.58+82.5%	-$0.47+89.8%	-$0.69+81.7%	-$2.32+68.6%
EPS (Diluted)	-$0.05	-$0.05	$1.08	-$0.38	-$0.58	-$0.47	-$0.69	-$2.32
Diluted Shares (Avg)	211M	210M	N/A	7M	5M	5M	N/A	2M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

PALI Balance Sheet

PALI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$134.3M+1134.8%	$10.9M-22.6%	$14.1M-10.9%	$15.8M+26.0%	$12.5M+314.4%	$3.0M-54.1%	$6.6M-14.3%	$7.7M-44.7%	$13.9M-38.6%	$22.6M+51.2%	$14.9M-49.9%	$29.8M+53.7%	$19.4M+121.9%	$8.8M+114.1%	$4.1M
Current Assets	$134.2M+1179.0%	$10.5M-21.3%	$13.3M-9.5%	$14.7M+28.0%	$11.5M+1184.2%	$896K-84.1%	$5.6M-13.2%	$6.5M-47.7%	$12.4M-40.4%	$20.9M+55.6%	$13.4M-52.3%	$28.2M+59.8%	$17.6M+130.2%	$7.7M+153.7%	$3.0M
Cash & Equivalents	$133.4M+1258.2%	$9.8M-21.0%	$12.4M+0.4%	$12.4M+18.0%	$10.5M+1371.9%	$713K-86.1%	$5.1M-11.6%	$5.8M-13.3%	$6.7M-56.1%	$15.2M+222.2%	$4.7M-62.3%	$12.5M-25.7%	$16.8M+126.3%	$7.4M+216.5%	$2.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$5.0M0.0%	$5.0M-33.5%	$7.5M-49.9%	$15.0M	$0	$0	$0
Accounts Receivable	$0	$0	N/A	$0	$0-100.0%	$59K+180.1%	$21K-92.8%	$294K-6.0%	$313K+2881.6%	$10K-71.9%	$37K-83.5%	$226K+2155.2%	$10K+200.0%	$3K-98.6%	$234K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.0M+46.5%	$3.4M+23.7%	$2.7M-16.6%	$3.3M-36.2%	$5.1M-73.8%	$19.6M+31.5%	$14.9M+812.3%	$1.6M-69.6%	$5.4M-52.4%	$11.3M+12.9%	$10.0M-17.7%	$12.1M+10.3%	$11.0M+518.6%	$1.8M-26.7%	$2.4M
Current Liabilities	$4.6M+43.3%	$3.2M+25.1%	$2.6M-14.1%	$3.0M+20.7%	$2.5M-69.1%	$8.1M+559.9%	$1.2M+16.5%	$1.1M-30.6%	$1.5M-79.3%	$7.3M+14.1%	$6.4M+60.3%	$4.0M-32.5%	$5.9M+238.0%	$1.8M-27.6%	$2.4M
Non-Current Liabilities	$328K+115.8%	$152K-0.7%	$153K-43.8%	$272K-89.7%	$2.7M-77.0%	$11.5M-15.7%	$13.7M+2245.4%	$584K-84.9%	$3.9M-2.2%	$3.9M+10.8%	$3.6M-56.2%	$8.1M+60.4%	$5.1M+23828.5%	$21K	$0
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$94K	N/A	N/A	N/A	N/A	$3.4M-58.0%	$8.1M+63.3%	$4.9M	$0	N/A
Total Equity	$129.4M+1626.9%	$7.5M-33.8%	$11.3M-9.3%	$12.5M+69.4%	$7.4M+144.4%	-$16.6M-99.3%	-$8.3M-237.7%	$6.0M-29.0%	$8.5M-24.8%	$11.3M+128.1%	$5.0M-72.0%	$17.7M+110.5%	$8.4M+20.7%	$7.0M+320.1%	$1.7M
Retained Earnings	N/A	$135.9M+11.9%	$121.5M+11.3%	$109.2M+15.4%	$94.6M+239.1%	-$68.0M+69.4%	-$222.0M-3.9%	-$213.6M-2.4%	-$208.7M-8.1%	-$193.0M-12.3%	-$172.0M-13.8%	-$151.1M-17.6%	-$128.4M-18.3%	-$108.6M-10.3%	-$98.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$127.3M+1809.6%	$133.3M+1527.8%	$134.3M+1134.8%	$7.0M-25.3%	$6.7M-48.2%	$8.2M-35.3%	$10.9M-22.6%	$9.3M-45.3%
Current Assets	$127.3M+1873.9%	$133.2M+1589.4%	$134.2M+1179.0%	$6.8M-23.0%	$6.4M-47.6%	$7.9M-34.3%	$10.5M-21.3%	$8.9M-45.5%
Cash & Equivalents	$125.2M+2210.7%	$132.6M+1734.4%	$133.4M+1258.2%	$5.2M-35.0%	$5.4M-52.3%	$7.2M-35.9%	$9.8M-21.0%	$8.0M-47.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$500K	N/A	$0	N/A	$0	N/A	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.6M+37.6%	$6.0M+108.2%	$5.0M+46.5%	$3.8M+37.9%	$4.0M+38.5%	$2.9M+10.5%	$3.4M+23.7%	$2.7M-8.6%
Current Liabilities	$5.2M+32.1%	$5.6M+102.4%	$4.6M+43.3%	$3.5M+29.7%	$4.0M+40.0%	$2.8M+12.6%	$3.2M+25.1%	$2.7M+1.2%
Non-Current Liabilities	$321K+316.9%	$333K+306.1%	$328K+115.8%	$283K+502.1%	$77K-10.5%	$82K-32.2%	$152K-0.7%	$47K-86.0%
Total Equity	$121.7M+4546.9%	$127.4M+2289.1%	$129.4M+1626.9%	$3.2M-51.4%	$2.6M-73.7%	$5.3M-47.0%	$7.5M-33.8%	$6.6M-53.1%
Retained Earnings	N/A	N/A	N/A	N/A	$141.0M+209.2%	$138.2M+210.6%	$135.9M+11.9%	$132.6M+11.9%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

PALI Cash Flow Statement

PALI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$18.2M	-$10.8M+11.0%	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.6%	-$14.8M-209.8%	-$4.8M+34.3%	-$7.3M+5.7%	-$7.7M+42.7%	-$13.4M+14.1%	-$15.6M+17.5%	-$18.9M-61.7%	-$11.7M-10.5%	-$10.6M-24.9%	-$8.5M-4.7%	-$8.1M
Depreciation & Amortization	N/A	$3K0.0%	$3K-25.0%	$4K+33.3%	$3K+50.0%	$2K-33.3%	$3K-97.9%	$144K-22.6%	$186K-35.8%	$289K-14.3%	$338K-2.3%	$345K-0.9%	$349K+42.5%	$245K+15.9%	$211K+12.9%	$187K
Stock-Based Compensation	N/A	$4.0M+506.6%	$652K+4.5%	$624K-39.5%	$1.0M-45.4%	$1.9M-6.1%	$2.0M+128.7%	$881K+38.9%	$634K-64.2%	$1.8M-48.6%	$3.4M+16.7%	$3.0M-31.7%	$4.3M+85.3%	$2.3M+44.7%	$1.6M-51.7%	$3.3M
Capital Expenditures	N/A	N/A	$0-100.0%	$4K-60.0%	$10K	$0-100.0%	$6K	N/A	$2K-85.0%	$11K-88.4%	$98K-44.4%	$176K-15.2%	$208K+65.8%	$125K+219.6%	$39K-80.0%	$196K
Free Cash Flow	N/A	N/A	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.5%	-$14.8M-209.4%	-$4.8M	N/A	-$7.7M+42.7%	-$13.4M+14.6%	-$15.7M+17.8%	-$19.1M-60.4%	-$11.9M-11.2%	-$10.7M-25.8%	-$8.5M-2.7%	-$8.3M
Investing Cash Flow	N/A	N/A	$0+100.0%	-$4K+60.0%	-$10K+81.5%	-$54K-800.0%	-$6K	N/A	$5.0M+5414.7%	-$94K-104.0%	$2.4M	N/A	N/A	N/A	-$255K+47.0%	-$481K
Financing Cash Flow	$138.0M	$134.4M+1303.0%	$9.6M-14.3%	$11.2M-26.7%	$15.3M-38.0%	$24.6M+1202.1%	$1.9M-71.3%	$6.6M+263.2%	$1.8M-63.6%	$5.0M-79.0%	$23.7M	N/A	N/A	N/A	$13.8M+728.6%	$1.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.6M-318.4%	-$3.9M-66.7%	-$3.1M-32.0%	-$3.6M-13.4%	-$1.8M+48.1%	-$2.3M+26.6%	-$2.4M+13.3%	-$3.1M-17.7%
Depreciation & Amortization	$0-100.0%	$0-100.0%	$0	$1K0.0%	$1K0.0%	$1K0.0%	$0	$1K0.0%
Stock-Based Compensation	$4.8M+7858.3%	$4.3M+6127.5%	N/A	$85K-7.6%	$60K-83.2%	$69K-41.5%	N/A	$92K-52.1%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$2.4M+13.3%	-$3.1M-17.7%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	$147K+3575.0%	$3.1M+1314.3%	$131.3M+3055.5%	$3.4M+1968.3%	$4K-99.9%	-$258K-112.7%	$4.2M+3206.0%	-$180K-111.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PALI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	-5228.0%	N/A	N/A	-68764.8%	-56071.8%	-3176.7%	-5118.1%	-127027.2%	-183896.8%	-92581.4%	-11385.4%	-2491.1%	-3325.6%
Net Margin	N/A	N/A	-4920.0%	N/A	N/A	-76346.1%	-54252.6%	-1894.1%	-6025.4%	-129721.8%	-200671.0%	-120154.7%	-18029.0%	-2482.5%	-3204.7%
Return on Equity	-13.0%+179.7pp	-192.7%-84.0pp	-108.7%+5.6pp	-114.3%+247.1pp	-361.4%	N/A	N/A	-81.4%+102.6pp	-184.0%+2.0pp	-186.0%+234.8pp	-420.8%-293.1pp	-127.7%+107.9pp	-235.6%-90.4pp	-145.2%+609.0pp	-754.2%
Return on Assets	-12.5%+120.2pp	-132.7%-45.2pp	-87.5%+2.9pp	-90.5%+122.3pp	-212.7%+129.2pp	-341.9%-215.1pp	-126.8%-62.8pp	-64.1%+48.7pp	-112.8%-19.6pp	-93.2%+46.6pp	-139.8%-64.0pp	-75.8%+26.3pp	-102.2%+13.5pp	-115.7%+190.7pp	-306.4%
Current Ratio	28.95+25.7x	3.24-1.9x	5.15+0.3x	4.89+0.3x	4.61+4.5x	0.11-4.5x	4.61-1.6x	6.19-2.0x	8.22+5.4x	2.85+0.8x	2.09-4.9x	7.03+4.1x	2.97-1.4x	4.36+3.1x	1.24
Debt-to-Equity	0.04-0.4x	0.45+0.2x	0.240.0x	0.26+0.3x	0.00	N/A	N/A	0.27-0.4x	0.63-0.4x	0.99+0.3x	0.68+0.2x	0.45-0.1x	0.59+0.6x	0.00-1.5x	1.46
Asset Turnover	0.000.0x	0.000.0x	0.020.0x	0.00	N/A	0.000.0x	0.000.0x	0.030.0x	0.020.0x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.050.0x	0.10
FCF Margin	N/A	N/A	-4454.8%	N/A	N/A	-35310.7%	N/A	-2959.3%	-5164.4%	-96726.6%	-183430.3%	-63264.4%	-9742.7%	-2089.0%	-2123.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-2339.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-2114.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-8.7%+97.6pp	-7.5%+34.3pp	N/A	-89.3%-36.5pp	-106.3%-65.3pp	-41.8%-6.8pp	N/A	-52.8%-27.2pp
Return on Assets	-8.3%+33.5pp	-7.2%+20.0pp	N/A	-41.1%-3.8pp	-41.8%-10.1pp	-27.2%+0.7pp	N/A	-37.4%-16.3pp
Current Ratio	24.26+22.6x	23.71+20.9x	28.95+25.7x	1.96-1.3x	1.62-2.7x	2.84-2.0x	3.24-1.9x	3.31-2.8x
Debt-to-Equity	0.05-1.5x	0.05-0.5x	0.04-0.4x	1.17+0.8x	1.54+1.3x	0.54+0.3x	0.45+0.2x	0.41+0.2x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Palisade Bio, Inc. PALI	FY2025	$0	-$16.8M	N/A	$250.9M	—
GRI Bio, Inc. GRI	FY2025	N/A	-$12.0M	N/A	$4.3M	—
Pasithea Therapeutics Corp. KTTA	FY2025	N/A	-$20.4M	N/A	$15.9M	—
60 Degrees Pharmaceuticals, Inc. SXTP	FY2025	$1.0M	-$7.4M	N/A	$4.9M	57/100
TITAN PHARMACEUTICAL INC TTNP	FY2024	N/A	-$4.7M	N/A	$6.1M	—
ADITXT INC ADTX	FY2025	$3K	-$43.1M	N/A	$34K	—

Where Palisade Bio, Inc. Ranks

Frequently Asked Questions

What is Palisade Bio, Inc.'s annual revenue?

Palisade Bio, Inc. (PALI) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Palisade Bio, Inc. profitable?

No, Palisade Bio, Inc. (PALI) reported a net income of -$16.8M in fiscal year 2025.

What is Palisade Bio, Inc.'s EBITDA?

Palisade Bio, Inc. (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Palisade Bio, Inc.'s return on equity (ROE)?

Palisade Bio, Inc. (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Palisade Bio, Inc.'s operating cash flow?

Palisade Bio, Inc. (PALI) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Palisade Bio, Inc.'s total assets?

Palisade Bio, Inc. (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Palisade Bio, Inc. spend on research and development?

Palisade Bio, Inc. (PALI) invested $10.2M in research and development during fiscal year 2025.

How many shares does Palisade Bio, Inc. have outstanding?

Palisade Bio, Inc. (PALI) had 166M shares outstanding as of fiscal year 2025.

What is Palisade Bio, Inc.'s current ratio?

Palisade Bio, Inc. (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.

What is Palisade Bio, Inc.'s debt-to-equity ratio?

Palisade Bio, Inc. (PALI) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Palisade Bio, Inc.'s return on assets (ROA)?

Palisade Bio, Inc. (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Palisade Bio, Inc.'s P/E ratio?

Palisade Bio, Inc. (PALI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $250.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Palisade Bio, Inc.'s price-to-sales ratio?

Palisade Bio, Inc. (PALI) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $250.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Palisade Bio, Inc.'s Piotroski F-Score?

Palisade Bio, Inc. (PALI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Palisade Bio, Inc.'s earnings high quality?

Palisade Bio, Inc. (PALI) reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Palisade Bio, Inc. cover its interest payments?

Palisade Bio, Inc. (PALI) reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.